Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary

Authors

Paul M Barr
Carolyn Owen
Tadeusz Robak
Alessandra Tedeschi
Osnat Bairey
Jan A Burger
Peter Hillmen
Claire Dearden
Sebastian Grosicki
Helen McCarthy
Jian Yong Li
Fritz Offner
Carol Moreno
Mandy Jermain
Cathy Zhou
Emily Hsu
Anita Szoke
Thomas J Kipps
Paolo Ghia

Publication Date

1-9-2023

Journal

Future Oncology

DOI

10.2217/fon-2022-0898

PMID

36617990

Abstract

What is this summary about?: This is a plain language summary of a publication describing long-term results from the RESONATE-2 study with up to 8 years of follow-up. The original paper was published in Blood Advances in June 2022.

What were the results?: Researchers looked at 269 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not received any treatment for their CLL/SLL. Study participants were randomly divided into two groups: 136 participants received treatment with a drug called ibrutinib, and 133 participants received treatment with a drug called chlorambucil. Participants in the study were treated and followed for up to 8 years, with results showing that more participants who took ibrutinib (59%) were alive without worsening of their disease at 7 years after starting treatment than participants who took chlorambucil (9%). Almost half of the participants (42%) were able to stay on ibrutinib treatment for up to 8 years.

What do the results of the study mean?: In people with CLL or SLL, more participants who were taking ibrutinib were alive without worsening of their disease after 7 years compared with participants who took chlorambucil. Clinical Trial Registration: NCT01722487 (ClinicalTrials.gov) Clinical Trial Registration: NCT01724346 (ClinicalTrials.gov).

Keywords

chronic lymphocytic leukemia, clinical trial, ibrutinib, lay summary, long-term efficacy, long-term safety, plain language summary, small lymphocytic lymphoma

Published Open-Access

yes

Recommended Citation

Barr, Paul M; Owen, Carolyn; Robak, Tadeusz; et al., "Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary" (2023). Faculty, Staff and Student Publications. 4270.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4270